U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H28N6O
Molecular Weight 428.5294
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRBESARTAN

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5

InChI

InChIKey=YOSHYTLCDANDAN-UHFFFAOYSA-N
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI

Molecular Formula C25H28N6O
Molecular Weight 428.5294
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

Curator's Comment: Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

8.7557761E11
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

8.7557761E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.3 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 μg/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.9 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.6 μg/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.3 μg/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.04 μg/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.9 μg/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.8 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
31.9 μg × h/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.6 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34.2 μg × h/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.8 μg × h/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.3 μg × h/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.7 μg × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15 h
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17 h
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11 h
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
IRBESARTAN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources: Page: p.247, p.250
healthy, 20-45
n = 9
Health Status: healthy
Age Group: 20-45
Sex: M+F
Population Size: 9
Sources: Page: p.247, p.250
Sources: Page: p.247, p.250
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension|diabetic nephropathy
Sources: Page: p.1
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources: Page: p.1
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Diabetic nephropathy
Sources: Page: p.6
Disc. AE: Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (2.1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Disorder fetal Disc. AE
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension|diabetic nephropathy
Sources: Page: p.1
Hyperkalemia 2.1%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Diabetic nephropathy
Sources: Page: p.6
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible
Page: 12.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Pharmacology of AT1-receptor blockers.
2001
Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.
2001
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
2001
Drug interactions with irbesartan.
2001
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].
2001
Hypertension and diabetes: the scope of the problem.
2001
Clinical differences among angiotensin II receptor antagonists.
2001
Pharmacological differences among angiotensin II receptor antagonists.
2001
Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.
2001
Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?
2001
The comparative pharmacology of angiotensin II receptor antagonists.
2001
Drug interaction: omeprazole and phenprocoumon.
2001
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
2001 Apr
Drug-induced cholestasis.
2001 Apr
Obese female SHHF/Mcc-fa(cp) rats resist antihypertensive effects of renin-angiotensin system inhibition.
2001 Apr
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
2001 Apr
Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
2001 Apr
[Angioedema due to irbesartan].
2001 Apr
Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.
2001 Apr 7
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
2001 Aug 9
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
2001 Dec
Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).
2001 Feb
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
2001 Jul
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
2001 Jul
Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor.
2001 Jul
The pharmacokinetics of irbesartan in hypertensive children and adolescents.
2001 Jul
Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
2001 Jul
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
2001 Jun
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
2001 Jun
Angiotensin II subtype 1 receptor blockers and renal function.
2001 Jun 25
Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure.
2001 Mar
Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.
2001 Mar
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
2001 May 31
Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
2001 Nov
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
2001 Nov 15
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
2001 Oct
Relation between clinical and therapeutic variables and quality of life in hypertension.
2001 Oct
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
2001 Oct
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
2001 Oct
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
2001 Oct
Angiotensin II receptor blockers and nephropathy trials.
2001 Oct
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
2001 Oct 1
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
2001 Oct 9
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.
2001 Sep
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
2001 Sep
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
2001 Sep
Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat.
2001 Sep 1
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
2001 Sep 20
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
2001 Sep-Oct
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.
2002 Jan
Patents

Sample Use Guides

Usual Adult Dose for Hypertension Initial dose: 150 mg orally once a day Maximum dose: 300 mg orally once a day Usual Adult Dose for Diabetic Nephropathy Target maintenance dose: 300 mg orally once a day Use: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (greater than 300 mg/day) in patients with type 2 diabetes and hypertension.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Contraction responses to increasing concentrations of Ang I (1 nM-1 uM) were evaluated in organ baths in the presence of captopril (10 uM-1 mM) with or without a chymase inhibitor (1 uM soybean trypsin inhibitor), or irbesartan (0.1 nM-uM), in internal mammary arteries from 25 patients undergoing coronary bypass surgery.
0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:09:26 UTC 2023
Edited
by admin
on Wed Jul 05 23:09:26 UTC 2023
Record UNII
J0E2756Z7N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IRBESARTAN
EMA EPAR   EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
Brand Name English
AVALIDE COMPONENT IRBESARTAN
Common Name English
IRBESARTAN [USP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF KARVEZIDE
Brand Name English
irbesartan [INN]
Common Name English
IRBESARTAN [MI]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
Brand Name English
IRBESARTAN ZENTIVA
Brand Name English
IRBESARTAN [USP-RS]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
Brand Name English
IRBESARTAN [EP IMPURITY]
Common Name English
SARBEVEL
Brand Name English
IRBESARTAN [VANDF]
Common Name English
IRBESARTAN TEVA
Brand Name English
IRBESARTAN [EMA EPAR]
Common Name English
IRBESARTAN [USAN]
Common Name English
IRBESARTAN COMPONENT OF IFIRMACOMBI
Brand Name English
COAPROVEL COMPONENT IRBESARTAN
Brand Name English
IRBESARTAN BMS
Brand Name English
BMS-186295
Code English
Irbesartan [WHO-DD]
Common Name English
IRBESARTAN [JAN]
Common Name English
IRBESARTAN [EP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF AVALIDE
Common Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA
Brand Name English
IFIRMACOMBI COMPONENT IRBESARTAN
Brand Name English
SR 47436
Code English
IRBESARTAN COMPONENT OF COAPROVEL
Brand Name English
SR-47436
Code English
IRBESARTAN [USP IMPURITY]
Common Name English
IRBESARTAN [ORANGE BOOK]
Common Name English
AVAPRO
Brand Name English
2-BUTYL-3-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE
Common Name English
NSC-758696
Code English
IRBESARTAN [MART.]
Common Name English
KARVEA
Brand Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS IFIRMACOMBI (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-ATC C09DA04
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS SARBEVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-ATC C09DB05
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS KARVEA (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
FDA ORPHAN DRUG 496715
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS COAPROVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
NCI_THESAURUS C66930
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
NDF-RT N0000175561
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
NDF-RT N0000000070
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS KARVEZIDE (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-VATC QC09DB05
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-VATC QC09CA04
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-ATC C09CA04
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
WHO-VATC QC09DA04
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
LIVERTOX NBK548450
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
Code System Code Type Description
FDA UNII
J0E2756Z7N
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
DRUG BANK
DB01029
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
WIKIPEDIA
IRBESARTAN
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
IUPHAR
589
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID0023169
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
MERCK INDEX
M6397
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY Merck Index
PUBCHEM
3749
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
RXCUI
83818
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY RxNorm
CHEBI
5959
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
LACTMED
Irbesartan
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
NSC
758696
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL1513
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
HSDB
8215
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
RS_ITEM_NUM
1347700
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
MESH
C081309
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
INN
7229
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
DAILYMED
J0E2756Z7N
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
CAS
138402-11-6
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
EVMPD
SUB08293MIG
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
SMS_ID
100000085443
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
DRUG CENTRAL
1481
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
NCI_THESAURUS
C29130
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
USAN
II-21
Created by admin on Wed Jul 05 23:09:26 UTC 2023 , Edited by admin on Wed Jul 05 23:09:26 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
FECAL; PLASMA; URINE
PARENT -> METABOLITE
approximately 15% of the urinary radioactivity.
PLASMA; URINE
METABOLITE -> PARENT
about 5% of the plasma radioactivity
PLASMA; URINE
METABOLITE -> PARENT
approximately 25% of the urinary radioactivity
MAJOR
URINE
METABOLITE -> PARENT
M5+M6+M7 is 24.2(iv) and 25.3 (oral) in feces. Plasma content should be very low
URINE
METABOLITE -> PARENT
Feces low and plasma negligible
URINE
METABOLITE -> PARENT
Low in feces and negligible in plasma
URINE
METABOLITE -> PARENT
M5+M6+M7 is 24.2(iv) and 25.3 (oral) in feces. Plasma content should be very low
URINE
PARENT -> METABOLITE
about 9% of the plasma radioactivity at 6 hr; was found to be more than 1000-fold less potent than irbesartan as an inhibitor
MAJOR
PLASMA
Related Record Type Details
IMPURITY GENOTOXIC->PARENT
NDMA is an organic chemical that is in a family of potent carcinogens.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
Priority toxic pollutant.
IMPURITY -> PARENT
Probable human carcinogen.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC